Levosimendan. Treatment of heart failure calcium sensitizer K(ATP) channel activator

Drugs of the Future

Volumn 25, Issue 6, 2000, Pages 563-568

  Toller, Wolfgang G ^a,b   Pagel, Paul S ^a   Kersten, Judy R ^a   Warltier, David C ^a,c  

^a CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF GRAZ   (Austria)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 [1 (3,4 DIMETHOXYBENZOYL) 1,2,3,4 TETRAHYDRO 6 QUINOLYL] 3,6 DIHYDRO 6 METHYL 2H 1,3,4 THIADIAZIN 2 ONE; INOTROPIC AGENT; LEVOSIMENDAN; PIMOBENDAN; SULMAZOLE;

DRUG ABSORPTION; DRUG HALF LIFE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CONTRACTILITY; HEART PROTECTION; HUMAN; INOTROPISM; LETHAL DOSE; MUSCLE RELAXATION; NONHUMAN; REVIEW;

EID: 0033944526     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2000.025.06.580665     Document Type: Review

References (32)

1. Packer, M., Carver, J.R., Rodeheffer, R.J et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. New Engl J Med 1991, 325: 1468-75.
2. Haikala, H., Kaivola, J., Nissinen, E., Wall, P., Levijoki, J., Linden, I.B. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995, 27: 1859-66.
3. 2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study. J Biol Chem 1994, 269: 28584-90.
4. 2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 1995, 77: 107-13.
5. Haikala, H., Nissinen, E., Etemadzadeh, E., Levijoki, J., Linden, I.B. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol 1995, 25: 794-801.
6. Varro, A., Papp, J.G. Classification of positive inotropic actions based on electrophysiologic characteristics: Where should calcium sensitizers be placed? J Cardiovasc Pharmacol 1995, 26: S32-44.
7. Haikala, H., Kaheinen, P., Levijoki, J., Linden, I.B. The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer. levosimendan. Cardiovasc Res 1997, 34: 536-46.
8. Pagel, P.S., Haikala, H., Pentikäinen, P.J, Toivonen, M.-L., Nieminen, M.S., Lehtonen, L., Papp, J.G., Warltier, D.C. Pharmacology of levosimendan: A new myofilament calcium sensitizer. Cardiovasc Drug Rev 1996, 14: 286-316.
9. + channel in rat ventricular cells. J Pharmacol Exp Ther 1997, 283: 375-83.
10. + channel in rat arterial myocytes. Eur J Pharmacol 1997, 333: 249-59.
11. 2+ transients in aequorin-loaded right ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit. J Mol Cell Cardiol 1998, 30: 1115-28.
12. Hasenfuss, G., Pieske, B., Rosenstiel, A. et al. Influence of levosimendan on isometric force and calcium cycling in failing human myocardium. Circulation 1994, 90(4, Part 2): Abst 1166.
13. Haikala, H., Levijoki, J., Linden, I.B. Troponin C-mediated calcium sensitization by levosimendan accelerates the proportional development of isometric tension. J Mol Cell Cardiol 1995, 27: 2155-65.
14. Pagel, P.S., McGough, M.F., Hettrick, D.A., Lowe, D., Tessmer, J.P., Jamali, I.N., Warltier, D.C. Levosimendan enhances left ventricular systolic and diastolic function in conscious dogs with pacing-induced cardiomyopathy. J Cardiovasc Pharmacol 1997, 29: 563-73.
15. Harkin, C.P., Pagel, P.S., Tessmer, J.P., Warltier, D.C. Systemic and coronary hemodynamic actions and left ventricular functional effects of levosimendan in conscious dogs. J Cardiovasc Pharmacol 1995, 26: 179-88.
16. Pagel, P.S., Harkin, C.P., Hettrick, D.A., Warltier, D.C. Zatebradine, a specific bradycardic agent, alters the hemodynamic and left ventricular mechanical actions of levosimendan, a new myofilament calcium sensitizer, in conscious dogs. J Pharmacol Exp Ther 1995, 275: 127-35.
17. ATP channels. Anesth Analg 2000, 90: 5-11.
18. Jamali, I.N., Kersten, J.R., Pagel, P.S., Hettrick, D.A., Warltier, D.C. Intracoronary levosimendan enhances contractile function of stunned myocardium. Anesth Analg 1997, 85: 23-9.
19. McGough, M.F., Pagel, P.S., Lowe, D., Hettrick, D.A., Kersten, J.R., Warltier, D.C. Effects of levosimendan on left ventricular function: Correlation with plasma concentrations in conscious dogs. J Cardiothorac Vasc Anesth 1997, 11: 49-53.
20. Sandell, E.P., Hayha, M., Antila, S., Heikkinen, P., Ottoila, P., Lehtonen, L.A., Pentikainen, P.J. Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure. J Cardiovasc Pharmacol 1995, 26: S57-62.
21. Sandell, E.P., Antila, S., Koistinen, H.H., Pentikainen, P.J. The effects of renal failure on the pharmacokinetics of levosimendan. Therapie (Suppl. 1) 1995, 50: S495.
22. Sandusky, G.E., Means, J.R., Todd, G.C. Comparative cardiovascular toxicity in dogs given inotropic agents by continuous intravenous infusion. Toxicol Pathol 1990, 18: 268-78.
23. Harleman, J.H., Joseph, E.C., Eden, R.J., Walker, T.F., Major, I.R., Lamb, M.S. Cardiotoxicity of a new inotrope/vasodilator drug (SK&F 94120) in the dog. Arch Toxicol 1986, 59: 51-5.
24. Lilleberg, J., Sundberg, S., Hayha, M., Akkila, J., Nieminen, M.S. Haemodynamic dose-efficacy of levosimendan in healthy volunteers. Eur J Clin Pharmacol 1994, 47: 267-74.
25. Lilleberg, J.M., Sundberg, S., Leikola-Pelho, T., Nieminen, M.S. Hemodynamic effects of the novel cardiotonic drug simendan: Echocardiographic assessment in healthy volunteers. Cardiovasc Drugs Ther 1994, 8: 263-9.
26. Sundberg, S., Lilleberg, J., Nieminen, M.S., Lehtonen, L. Hemodynamic and neurohumoral effects of levosimendan, a new calcium sensitizer, at rest and during exercise in healthy men. Am J Cardiol 1995, 75: 1061-6.
27. Lehtonen, L., Mills-Owens, P., Akkila, J. Safety of levosimendan and other calcium sensitizers. J Cardiovasc Pharmacol 1995, 26: S70-6.
28. Lilleberg, J., Sundberg, S., Nieminen, M.S. Dose-range study of a new calcium sensitizer, levosimendan, in patients with left ventricular dysfunction. J Cardiovasc Pharmacol 1995, 26: S63-9.
29. Antila, S., Eha, J., Heinpalu, M., Lehtonen, L., Loogna, I., Mesikepp, A., Planken, U., Sandell, E.P. Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril. Eur J Clin Pharmacol 1996, 49: 451-8.
30. Nijhawan, N., Nicolosi, A.C., Montgomery, M.W., Aggarwal, A., Pagel, P.S., Warltier, D.C. Levosimendan enhances cardiac performance after cardiopulmonary bypass: A prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol 1999, 34: 219-28.
31. Lilleberg, J., Nieminen, M.S., Akkila, J., Heikkila, L., Kuitunen, A., Lehtonen, L., Verkkala, K., Mattila, S., Salmenpera, M. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 1998, 19: 660-8.
32. Orion highlights R&D developments for 1999. DailyDrugNews.com (Daily Essentials) March 8, 2000.